Dow Jones Newswires: Roche says Phase 3 studies for Alzheimer’s drug failed to meet primary…
Roche Holding AG said Monday that Phase 3 Graduate studies of gantenerumab, for treatment of early Alzheimer’s disease, failed to meet its primary endpoints. The Swiss pharma…